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A 26-year-old womanwith gross hematuria was seen in a previous hospital. Magnetic resonance imaging
(MRI) showed a tumor at the dome of the urinary bladder with invasion outside of the bladder wall. The
patient underwent transurethral resection of the bladder tumor (TUR-BT). From the result of the path-
ological examination, the tumor was suggested to be carcinosarcoma of the bladder. The patient was
then referred to our hospital for treatment. We performed radical cystectomy and ileal conduit diversion.
Pathological examination of the excised specimen revealed an inﬂammatory myoﬁbroblastic tumor as
the basis for immunostaining of anaplastic lymphoma kinase (ALK).
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Inﬂammatory myoﬁbroblastic tumor (IMT) is a distinctive
neoplasm composed of myoﬁbroblastic and ﬁbroblastic spindle
cells accompanied by an inﬂammatory inﬁltration of plasma cells,
lymphocytes, and/or eosinophils. Because of its histologic features,
it can be difﬁcult to distinguish from other sarcomatoid tumors
such as urothelial carcinoma sarcomatoid variant and leiomyo-
sarcoma. We report a case of IMT, who underwent radial cys-
tectomy at the diagnosis of carcinosarcoma of the bladder. ALK
(anaplastic lymphoma kinase) gene translocation or ALK protein
expression in IMT has been reported. We discuss the usefulness of
ALK immunostaining and molecular biological analysis of the ALK
gene in the differential diagnosis of IMT.Case presentation
A 26-year-old woman presented to another hospital with gross
hematuria. Computed tomography of the abdomen and pelvis; MRI, Magnetic resonance
tory myoﬁbroblastic tumor;
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Inc. This is an open access article urevealed a 33-mm enhancing mass arising from the dome of the
urinary bladder. Dynamic MRI of the bladder revealed an early
enhancing lobulated bladder tumor inﬁltrating to the outside of the
bladder wall (Fig. 1). Cystoscopy revealed a solitary non-papillary
tumor with surrounding edema. The patient presented with se-
vere anemia due to hematuria, and transurethral resection of the
bladder tumor (TUR-BT) and coagulation were promptly per-
formed. The pathological ﬁndings of the TUR-BT specimen showed
spindle cell proliferationwith enlarged nuclei, and immunostaining
showed that the tumor was positive for both cytokeratin AE1/AE3
and vimentin, and the rate of MIB-1 positivity was 40%. The tumor
was suggested to be a urothelial carcinoma sarcomatoid variant of
the bladder. Thereafter, the patient was referred to our hospital for
further treatment.
After we reviewed the pathological examination of the TUR-BT
specimen, we diagnosed the patient as having carcinosarcoma of
the bladder (cT3aN0M0). Because this was a high-grade carcinoma,
we performed radical cystectomy and ileal conduit diversion with
the emphasis on radical surgery. The pathological examination of
excised specimen showed proliferation of spindle cells expanding
mainly into the bladdermusculature accompanied by inﬂammatory
cell inﬁltrate (Fig. 2). Immunostaining showed that the tumor cells
were positive for ALK-1, vimentin, and smooth muscle actin. Cyto-
keratin AE1/AE3 staining was diffusely positive, and p63 staining
was uniformly negative. From the histomorphology and immuno-
phenotype, the tumor was deﬁnitively diagnosed as IMT of thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Sagittal contrast-enhanced MRI of the urinary bladder revealed early
enhancement of a lobulated bladder tumor on the dome inﬁltrating to the outside of
the bladder wall.
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BT. To date, the patient has been followed for 10 months with no
evidence of recurrence.Discussion
IMT is a rare neoplasm that occurs primarily in soft tissue and
viscera. It is classiﬁed as intermediate (rarely metastasizing) inFigure 2. Histopathological ﬁndings revealed spindle cells and nuclear atypia (H&E
staining, 200).the WHO classiﬁcation of soft tissue tumors. Approximately 25%
of extrapulmonary IMTs recur, and metastasis occurs in <2% of
cases. IMT occurs most frequently in the mesentery, omentum,
retroperitoneum, pelvis, and abdominal soft tissue in 73% of
cases.1 Its occurrence in the urinary bladder is unusual. A recent
review article showed that IMT of the urinary bladder occurs at a
mean age of 38.9 years with a predilection for females (51.7%).2
The most common presentation is hematuria followed by
dysuria, urinary frequency, and other symptoms. Characteristic
pathological ﬁndings include the presence of spindle cells, myo-
ﬁbroblastic and ﬁbroblastic cells, and inﬂammatory cells con-
sisting mainly of plasma cells and lymphocytes. IMT may be
difﬁcult to distinguish pathologically from urothelial carcinoma
sarcomatoid variant and leiomyosarcoma because of its
morphology.
According to a research article on the discrepancy in histo-
pathological diagnosis of soft tissue tumors, following retrospective
pathological review of patients referred with soft tissue lesions to a
specialist in soft tissue sarcoma, either major or minor discrep-
ancies between the referring and ﬁnal diagnosis were present in
28.2% of cases. Additional immunohistochemical andmolecular and
molecular cytogenetic tests contributed to a change in the ﬁnal
diagnosis in 30.6% of all discrepant cases.3
In the present case, there was a diagnostic discrepancy between
the TUR-BT specimen and the excised specimen. The deciding factor
in changing the diagnosis was made in accordance with the
immunohistochemical ﬁnding of ALK-1. At ﬁrst, the spindle cells
with swollen nuclei looked like carcinosarcoma in the TUR-BT
specimen, but on examination of the excised specimen, although
there were some enlarged nuclei with obvious nucleoli, there were
no tumor cells with an epithelial morphology. After we noted the
spindled cells and inﬁltrate with diffuse inﬂammation and positive
immunoreactivity of ALK-1, the tumor was diagnosed as IMT of the
urinary bladder.
ALK gene translocation in non-small-cell lung cancer was
initially reported in 2007 by Soda et al.4 IMTs were also noted to
have ALK gene rearrangements, and cytoplasmic reactivity for ALK
protein is detectable in 50%-60% of IMTs, which correlates well with
the presence of a rearrangement of the ALK gene.1 ALK-1 proteinFigure 3. Fluorescence in situ hybridization analysis. White arrowheads indicate sig-
nals positive for ALK gene rearrangements.
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ferential diagnosis of IMTs versus sarcomatoid carcinomas because
these genetic rearrangements have not been documented in the
sarcomatoid carcinomas.
Fluorescence in situ hybridization is useful in detecting ALK gene
translocation and was used to detect the ALK gene translocation in
this case (Fig. 3). In the ﬁeld of lung cancer, ALK gene translocation is
reported to respond well to an ALK inhibitor, and molecularly tar-
geted therapy with crizotinib has already been applied in the
clinical setting. In view of the benign course of IMT, complete
resection of the tumor is considered to be the standard therapy.
However, the course in some patients behaves in a malignant
manner.5 Molecular targeted therapy is expected to have a role in
the treatment of such patients in the future.Conﬂict of interest
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